Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

14.77EUR
17 Feb 2017
Change (% chg)

-- (--)
Prev Close
€14.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,873
52-wk High
€19.90
52-wk Low
€9.06

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): €569.11
Shares Outstanding(Mil.): 38.53
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 28.47 29.39
EPS (TTM): -0.81 -- --
ROI: -159.52 13.57 13.06
ROE: -- 14.45 14.19

BRIEF-AB Science issues 520,091 new shares

* Issues 520,091 new shares at a unit price of 14.62 euros ($15.54)/share Source text for Eikon: Further company coverage: ($1 = 0.9411 euros) (Gdynia Newsroom)

Jan 13 2017

BRIEF-AB Science announces publication of pivotal phase 3 study masitinib results

* In pivotal phase 3 study masitinib administered at 6 mg/kg/day was significantly superior to placebo

Jan 09 2017

BRIEF-Ab Science announces update on masitinib

* Announces the filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European medicines agency

Sep 29 2016

BRIEF-AB Science H1 net loss widens to 14.8 million euros

* H1 net loss of 14.8 million euros versus loss of 13.0 million euros ($14.49 million) year ago

Aug 31 2016

More From Around the Web

Earnings vs. Estimates